Browsing Tag
National Medical Products Administration
19 posts
Could subcutaneous PD-1 therapy reshape oncology treatment logistics in China?
Could subcutaneous PD-1 therapy reshape cancer treatment in China? Explore Junshi Biosciences’ toripalimab filing and its impact on oncology logistics.
Akeso secures fifth NMPA breakthrough therapy designation for ivonescimab, sharpening its first-line oncology ambitions in China
Akeso Inc. secures a fifth breakthrough therapy designation for ivonescimab. Find out why this matters for oncology strategy and investors.
GSK wins approval in China for Nucala in eosinophilic COPD, expanding respiratory biologics reach
Find out how GSK’s Nucala just became the first biologic approved for eosinophilic COPD in China—and what it means for the future of respiratory care.
Innovent Biologics secures FDA greenlight for first global Phase 3 trial of IBI363 in lung cancer
Innovent Biologics wins FDA approval for its first global Phase 3 trial of IBI363 in lung cancer, signaling a major milestone in immuno-oncology.
Zai Lab stock rallies on regulatory optimism in China’s oncology sector
Zai Lab stock jumps 7.6% on China FDA review optimism for its oncology drugs, as cross-border biotech sentiment improves. Read the full investor analysis.
Innovent’s IBI363 gains NMPA breakthrough therapy designation, boosting regulatory momentum
Innovent’s IBI363 secures NMPA breakthrough therapy designation for melanoma. Discover its clinical potential, investment outlook, and global impact.
CARsgen advances CAR T-cell therapies with breakthrough designation for satri-cel and first dose of KJ-C2219
CARsgen Therapeutics Holdings Limited has taken significant strides in the field of CAR T-cell therapy with two major…
Akeso’s Gumokimab poised to redefine Psoriasis treatment
Akeso, Inc., a leading biopharmaceutical innovator based in Hong Kong, is making significant strides in the treatment of…
Keymed Biosciences secures NMPA approval for Stapokibart in chronic rhinosinusitis treatment
Keymed Biosciences Inc. (HKEX: 02162) has received a significant regulatory endorsement as the National Medical Products Administration (NMPA)…
Sanofi strengthens cardiovascular portfolio with Aficamten rights in Greater China
Cytokinetics, Incorporated (NASDAQ: CYTK) saw its shares climb by 4.8% after announcing a landmark agreement with Sanofi (NASDAQ:…